Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 3/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.40 |
| ▸ | SCN4A | P35499 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2801968 | 0.88 | SCN4A (0.43) | SCN4APOLBGRIN2B | |
| SCHEMBL13196711 | 0.85 | CCR5 (0.38) | JAK2JAK1CCR5GPR119NR1I2 | |
| SCHEMBL13200870 | 0.85 | CCR5 (0.38) | JAK2JAK1CCR5GPR119NR1I2 | |
| SCHEMBL13196693 | 0.85 | CACNA1G (0.43) | JAK2JAK1CCR5 | |
| SCHEMBL13201163 | 0.85 | CACNA1G (0.43) | JAK2JAK1CCR5 | |
| SCHEMBL13200887 | 0.82 | CCR5 (0.36) | JAK2JAK1CCR5GPR119NR1I2 | |
| SCHEMBL13196707 | 0.82 | CCR5 (0.36) | JAK2JAK1CCR5GPR119NR1I2 | |
| SCHEMBL16064467 | 0.81 | CCR5 (0.52) | JAK2JAK1CCR5GPR119TP53 | |
| SCHEMBL18495417 | 0.81 | CCR5 (0.52) | JAK2JAK1CCR5GPR119TP53 | |
| SCHEMBL5746496 | 0.80 | GRIN2B (0.44) | SCN4APOLBGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197724-A1 | 6.5 -PYRROLOPIPERIDINE TACHYKININ RECEPTOR ANTAGONISTS | BAO JIANMING | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197724-A1 | 6.5 -PYRROLOPIPERIDINE TACHYKININ RECEPTOR ANTAGONISTS | TACR1, TACR2, HTR1D | JAK2 1228/4885JAK1 904/4885CCR5 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.